BioCentury on BioBusiness,
Focus on 18 commissioners; Bioethical burden
Monday, March 10, 1997
WASHINGTON - There was a great deal of talk last week about the implications of cloning - in Congress, the White House, on TV and around kitchen tables - and there will be more this week, with the Dolly doctor himself, Ian Wilmot; NIH Director Harold Varmus; Genzyme Transgenics Corp. President and CEO James Geraghty; and Alexion Pharmaceuticals Inc. President and CEO Leonard Bell scheduled to testify to Congress.
But perhaps the most significant conversations this week will be heard at a two-day hearing of the 18 members of the National Bioethics Advisory Commission (NBAC). Varmus has urged Congress to defer action until it hears from the commission. And President Clinton, even while announcing a ban on federal funding of cloning research and calling for the private sector to respect a voluntary prohibition, said the measures were temporary stop-gaps until the NBAC completes a 90-day report on the issue (see BioCentury Extra, Feb. 25).
Language is crucial
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]